Zobrazeno 1 - 10
of 25
pro vyhledávání: '"M. Isabel Sáez"'
Autor:
M. Isabel Sáez, Alba Galafat, Antonio J. Vizcaíno, Cristina Rodríguez, Alma Hernández de Rojas, F. Javier Alarcón, Tomás F. Martínez
Publikováno v:
Frontiers in Marine Science, Vol 9 (2022)
This study raises the question of the potential long-term effects of a feeding pulse with diets containing algal biomass on the quality of frozen turbot (Scophthalmus maximus) fillets. A feeding trial was carried out with this aim, in which juvenile
Externí odkaz:
https://doaj.org/article/064798b2b6de49c485fb0bed51ef9d43
Autor:
Pablo Maroto, Javier Cassinello, Martin Lázaro Quintela, Jose Angel Arranz Arija, Emilio Esteban, Ignacio Duran, Alfredo Sanchez-Hernandez, Daniel Castellano, María José Juan Fita, Miguel Angel Climent Duran, Javier Puente, Teresa Alonso Gordoa, María José Méndez Vidal, Albert Font, Begoña Mellado, Aranzazu Gonzalez del Alba, Carmen Santander, M Isabel Sáez, Begoña P. Valderrama
Publikováno v:
Journal of Clinical Oncology. 38:95-95
95 Background: Abiraterone acetate (AA) improves OS and rPFS in first line mCRPC patients (pts). After AA progression D is commonly used as standard second line therapy. However, the value of maintaining AA in combination with D despite progression h
Autor:
Enrique Gallardo Diaz, Sergio Vazquez-Estevez, Maria Piedad Fernandez Perez, Begoña Mellado, Ignacio Duran, Enrique Gonzalez-Billalabeitia, Miguel Angel Climent, Aranzazu Gonzalez del Alba, Carmen Santander, M.J. Méndez-Vidal, M Isabel Sáez, Ovidio Fernandez Calvo, Angel Sánchez, Enrique Grande, Javier Puente, Elena Castro, Gerhardt Attard, Daniel Wetterskog, Albert Font Pous, Daniel Castellano
Publikováno v:
Journal of Clinical Oncology. 37:5040-5040
5040 Background: TMPRSS2-ERG fusion gene is a common driver of prostate cancer. The PREMIERE study is a phase II, single arm open-label, multicentre, clinical trial designed to analyse the predictive/prognostic value of TMPRSS2-ERG in first-line chem
Autor:
A. Montesa, Fernando López-Campos, Javier Puente, M Isabel Sáez, Josep M. Piulats, Casilda Llacer Perez, M.J. Méndez-Vidal, David Olmos, Elena Almagro, Rafael Morales-Barrera, Nuria Romero-Laorden, Nuria Lainez, Elena Castro, David Lorente, Alejo Rodriguez Vida, Rebeca Lozano, Susana Hernando Polo, Amaia Hernandez, B. Pérez-Valderrama, Eva Fernandez
Publikováno v:
Journal of Clinical Oncology. 37:267-267
267 Background: Abiraterone, enzalutamide and docetaxel represent first-line (1L) treatment options in mCRPC. A significant correlation between rPFS and OS has been reported for patients treated with 1L abi and enza in mCRPC. It is however unclear wh
Autor:
Alejandro gonzalez Forastero, Ignacio Duran, Cristina Caballero Diaz, Isabel Chirivella, A. Montesa, David Olmos, Lucia Heras, M Isabel Sáez, María José Juan Fita, Sergio Vazquez-Estevez, Begoña Mellado, Josep M. Piulats, Miguel Angel Climent Duran
Publikováno v:
Journal of Clinical Oncology. 37:198-198
198 Background: Different treatments efficacy for mCRPC when progression after docetaxel x 6 cycles + ADT (as CHAARTED scheme) are unknown as all pivotal trials where performed in patients who progressed to mCPRC after ADT. Methods: A retrospective a
Autor:
Lacave, M Isabel Sáez1 maribel.saez@uam.es, Gutiérrez, Nuria Bermejo1 nuria.bermejo@uam.es
Publikováno v:
European Business Organization Law Review. Sep2010, Vol. 11 Issue 3, p423-458. 36p.
Autor:
O. Fernández, José García-Sánchez, Beatriz Suarez-Paniagua, Jose Carlos Villa Guzman, Carmen Santander-Lobera, Núria Sala-González, Miguel A. Climent-Duran, Montserrat Domenech, Nuria Lainez, Sergio Vazquez-Estevez, Enrique Gallardo, Marina Morán, Javier Puente, Martín Lázaro-Quintela, Cristina Caballero-Díaz, Emilio Esteban, Carmen Molins, Alvaro Pinto-Marin, F.J. Afonso, Maria Jose Lecumberri, Laura Basterretxea, Ricardo Sánchez-Escribano, Daniel Castellano, María Belén González, Iciar García-Carbonero, Marta López-Brea, Isabel Chirivella, Esther Martínez-Ortega, David Marrupe, M Isabel Sáez, Aranzazu Gonzalez del Alba, Irene Gil-Arnaiz, Begoña Mellado, Cristina Suárez-Rodríguez, Eva Fernandez Parra, Jesús García-Donas, María José Méndez-Vidal, Luis León
Publikováno v:
BMC Cancer
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
BMC CANCER
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
BMC CANCER
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
r-FISABIO. Repositorio Institucional de Producción Científica
Background: The impact of such recommendations after their implementation of guidelines has not usually been evaluated. Herein, we assessed the impact and compliance with the Spanish Oncology Genitourinary Group (SOGUG) Guidelines for toxicity manage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098b002929478ade98738ca4ac0a59b8
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1231
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1231
Autor:
Elena Castro, Jose Maria M. Piulats Rodriguez, Enrique Gonzalez-Billalabeitia, David Lorente, Pablo Borrega, Rebeca Lozano, Alejo Rodriguez Vida, Aranzazu Gonzalez del Alba, Rafael Morales Barrera, Angela del Pozo, Iciar Garcia Carbonero, Pablo Lapunzina, Javier Puente, M Isabel Sáez, Eva Fernandez Parra, Nuria Romero-Laorden, María José Méndez-Vidal, Ana Medina, David Olmos, Colin C. Pritchard
Publikováno v:
Journal of Clinical Oncology. 36:5071-5071
5071Background: Germline mutations in BRCA2 have been identified in 3-5% of mCRPC patients. PROREPAIR-B (Castro et al ESMO 2017) is the first prospective study to report a worse survival from mCRPC...
Autor:
Alejandro Herrador, Enrique Gallardo Diaz, Jose Maria Roldan, Javier Puente, Nuria Lainez, Cristina Rodríguez-Antona, Maria José Santos, Jose Angel Arranz, Juan Francisco Rodriguez-Moreno, Emilio Esteban Gonzalez, Miguel Angel Climent, A. Gutiérrez, Aranzazu Gonzalez del Alba, Montserrat Domenech, Daniel Castellano, Teresa Alonso Gordoa, Jesús GarcÃa-Donas, Laura Rodriguez, M Isabel Sáez, Susana Hernando Polo
Publikováno v:
Journal of Clinical Oncology. 36:4559-4559
4559Background: The development of new combinations with mTOR inhibitors and the description of meaningful responses in cases with mutations in the mTOR pathway have raised the interest on these co...
Autor:
Karrie Wang, Mary-Ellen Taplin, Benjamin H Lowentritt, Wassim Abida, Geraldine Ferron-Brady, David R. Wise, Olena Barbash, Begoña Mellado, Vivek Narayan, Doug Fecteau, Joshua Michael Lang, Joan Carles, Arindam Dhar, Johann S. de Bono, Arun Azad, M Isabel Sáez, Ahmed Khaled, Ulka N. Vaishampayan
Publikováno v:
Journal of Clinical Oncology. 36:TPS391-TPS391
TPS391 Background: Metastatic castrate-resistant prostate cancer (mCRPC) remains an incurable illness as resistance develops after androgen deprivation therapy (ADT) and/or androgen receptor (AR) axis targeted therapies. The bromodomain (BRD) and ext